• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.

作者信息

Chen Xiaolong, Zheng Yuguo, Shen Yinchu

机构信息

Institute of Bioengineering, Zhejiang University of Technology, Hangzhou 310032, PR China.

出版信息

Curr Med Chem. 2006;13(1):109-16. doi: 10.2174/092986706789803035.

DOI:10.2174/092986706789803035
PMID:16457643
Abstract

The number of people with diabetes is expected to rise from the current estimated 150 million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM). Voglibose, one of the most important alpha-glucosidase inhibitors, delays the digestion and absorption of carbohydrates, thereby inhibiting postprandial hyperglycemia and hyperinsulinemia, and is the aid in the treatment of diabetes. In this paper, properties and the preparation of voglibose are reviewed.

摘要

相似文献

1
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Curr Med Chem. 2006;13(1):109-16. doi: 10.2174/092986706789803035.
2
[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].伏格列波糖(一种α-葡萄糖苷酶抑制剂)治疗糖耐量减低的效果
Nihon Rinsho. 2005 Feb;63 Suppl 2:457-61.
3
Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.伏格列波糖(AO - 128)是一种有效的α - 葡萄糖苷酶抑制剂,可调动内源性胰高血糖素样肽 - 1储备。
Digestion. 1995;56(6):493-501. doi: 10.1159/000201282.
4
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.非胰岛素依赖型糖尿病患者胃排空与α-葡萄糖苷酶抑制剂对餐后高血糖的作用之间的关系。
Diabetes Care. 1997 Oct;20(10):1529-32. doi: 10.2337/diacare.20.10.1529.
5
[alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].[α-葡萄糖苷酶抑制剂及其抗糖尿病作用的结构与机制]
Nihon Rinsho. 2002 Sep;60 Suppl 9:393-8.
6
Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.同时给予α-葡萄糖苷酶抑制剂伏格列波糖(AO-128)不会改变格列本脲的药代动力学。
Eur J Clin Pharmacol. 1997;53(2):149-52. doi: 10.1007/s002280050354.
7
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage].[一名患有由脑出血引起步态障碍的老年糖尿病患者在服用伏格列波糖后发生肠梗阻]
Nihon Ronen Igakkai Zasshi. 1996 Aug;33(8):607-12. doi: 10.3143/geriatrics.33.607.
8
Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.两种α-葡萄糖苷酶抑制剂伏格列波糖和阿卡波糖对餐后高血糖的影响与主观腹部症状相关。
Metabolism. 2005 Mar;54(3):387-90. doi: 10.1016/j.metabol.2004.10.004.
9
Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.α-葡萄糖苷酶抑制剂 voglibose 抑制糖尿病和肥胖小鼠氧化偶氮甲烷诱导的结肠前肿瘤病变。
Int J Mol Sci. 2020 Mar 23;21(6):2226. doi: 10.3390/ijms21062226.
10
The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.α-葡萄糖苷酶抑制剂伏格列波糖(AO - 128)不会改变华法林的药效学或药代动力学。
Eur J Clin Pharmacol. 1997;53(2):153-7. doi: 10.1007/s002280050355.

引用本文的文献

1
Diverse Library of 5a-Substituted Carba-Glucosamines.5a-取代碳环葡糖胺的多样文库。
J Org Chem. 2025 Feb 28;90(8):2969-2977. doi: 10.1021/acs.joc.4c02816. Epub 2025 Feb 15.
2
In Vitro Anti-diabetic Activity of Pomegranate Peel Extract-Mediated Strontium Nanoparticles.石榴皮提取物介导的锶纳米颗粒的体外抗糖尿病活性
Cureus. 2023 Dec 30;15(12):e51356. doi: 10.7759/cureus.51356. eCollection 2023 Dec.
3
Antioxidant and Antidiabetic Properties of Phlorotannins from Seaweed Extracts.海藻提取物中岩藻黄质的抗氧化和抗糖尿病特性。
Molecules. 2023 Jun 23;28(13):4937. doi: 10.3390/molecules28134937.
4
Allylic Carbocyclic Inhibitors Covalently Bind Glycoside Hydrolases.烯丙基碳环抑制剂与糖苷水解酶共价结合。
JACS Au. 2023 Mar 20;3(4):1151-1161. doi: 10.1021/jacsau.3c00037. eCollection 2023 Apr 24.
5
Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes.植物成分α-葡萄糖苷酶抑制剂的最新进展:一种治疗2型糖尿病的方法
Plants (Basel). 2022 Oct 14;11(20):2722. doi: 10.3390/plants11202722.
6
Carbohydrate-based drugs launched during 20002021.2000年至2021年期间推出的碳水化合物类药物。 (你提供的原文“20002021”表述有误,推测应该是“2000 - 2021” )
Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23.
7
Heterocyclic compounds as a magic bullet for diabetes mellitus: a review.杂环化合物作为糖尿病的神奇疗法:综述
RSC Adv. 2022 Aug 16;12(35):22951-22973. doi: 10.1039/d2ra02697j. eCollection 2022 Aug 10.
8
Strategies for the Development of Glycomimetic Drug Candidates.糖模拟候选药物的开发策略。
Pharmaceuticals (Basel). 2019 Apr 11;12(2):55. doi: 10.3390/ph12020055.
9
Gene cloning and expression of a glucoside 3-dehydrogenase from Sphingobacterium faecium ZJF-D6, and used it to produce N-p-nitrophenyl-3-ketovalidamine.屎黄杆菌ZJF-D6中一种葡糖苷3-脱氢酶的基因克隆与表达,并将其用于生产N-对硝基苯基-3-酮缬氨霉素。
World J Microbiol Biotechnol. 2017 Feb;33(2):21. doi: 10.1007/s11274-016-2187-0. Epub 2017 Jan 2.
10
Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2.间苯三酚单宁:迈向2型糖尿病的新药理学干预措施
Molecules. 2016 Dec 30;22(1):56. doi: 10.3390/molecules22010056.